You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 24, 2024

PROVAYBLUE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Provayblue patents expire, and what generic alternatives are available?

Provayblue is a drug marketed by Provepharm Sas and is included in one NDA.

The generic ingredient in PROVAYBLUE is methylene blue. There are twenty-five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the methylene blue profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Provayblue

A generic version of PROVAYBLUE was approved as methylene blue by ZYDUS LIFESCIENCES on December 5th, 2023.

  Sign Up

AI Research Assistant
Sample questions
  • What is the 5 year forecast for PROVAYBLUE?
  • What are the global sales for PROVAYBLUE?
  • What is Average Wholesale Price for PROVAYBLUE?
Drug patent expirations by year for PROVAYBLUE
Drug Prices for PROVAYBLUE

See drug prices for PROVAYBLUE

Recent Clinical Trials for PROVAYBLUE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Carilion ClinicPhase 2
Provepharm Life SolutionsPhase 2
Provepharm SASPhase 4

See all PROVAYBLUE clinical trials

Pharmacology for PROVAYBLUE

US Patents and Regulatory Information for PROVAYBLUE

PROVAYBLUE is protected by zero US patents and one FDA Regulatory Exclusivity.

FDA Regulatory Exclusivity protecting PROVAYBLUE

INFORMATION ADDED TO THE CLINICAL STUDIES SECTION TO FULFILL A POST-MARKETING REQUIREMENT
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Provepharm Sas PROVAYBLUE methylene blue SOLUTION;INTRAVENOUS 204630-002 Jul 18, 2019 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Provepharm Sas PROVAYBLUE methylene blue SOLUTION;INTRAVENOUS 204630-001 Apr 8, 2016 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.